Prostate cancer — all decisions

The Board granted service connection for prostate cancer, resolving all doubt in the Veteran's favor and finding that his prostate cancer is related to his in-service toxic exposures.

The Board remands the claim for a medical opinion to determine if the Veteran's prostate cancer was caused by exposure to herbicides while serving in the Korean DMZ.

The Board remands the claim for service connection for prostate cancer for readjudication due to new and relevant evidence being submitted.

The Board denied the veteran's claims for increased ratings for erectile dysfunction, prostate cancer status post radical prostatectomy, and scars, status post radical prostatectomy.

The Board denied the Veteran's claim for service connection for prostate cancer, finding that the evidence does not support a link between the condition and his military service.

The Board denied the veteran's claims for earlier effective dates, higher ratings, and remanded several service connection claims.

The Board denied the Veteran's claims for earlier effective dates for service connection for prostate cancer, erectile dysfunction, and CAD, as these were granted under the PACT Act on August 10, 2022.

The Board granted a 60 percent rating for residuals of prostate cancer from August 10, 2022 to June 5, 2023 and denied a higher rating from June 5, 2023. The Board also remanded the issue of entitlement to a total disability rating based on individual unemployability due to service-connected disability (TDIU).

The Board remands the claims for service connection for hypertension and prostate cancer to verify the Veteran's claimed exposure to herbicide agents in the DMZ.

The Board denied the veteran's claim for service connection for prostate cancer, finding no medical evidence linking his condition to his service or exposure at Camp Lejeune.

The Board denied service connection for diabetes mellitus, prostate cancer, rectal cancer, weak bladder as secondary to prostate cancer, and blood in urine/stool as secondary to rectal cancer due to lack of evidence supporting a causal relationship between the conditions and exposure to contaminated water at Camp Lejeune.

The Board remands the claim for service connection for prostate cancer due to an inadequate VA medical opinion and a need for additional evidence regarding the Veteran's treatment records.

The Board remands the claims for service connection for prostate cancer and skin cancer (basal cell carcinoma) to provide the Veteran with VA examinations and opinions regarding the etiology of these conditions, including considering toxic exposure risk activities.

The Board granted service connection for autoimmune hepatitis and prostate cancer based on new evidence showing a relationship to toxic exposure during service.

The proposed severance of service connection for prostate cancer was dismissed as the August 2024 rating decision was not a final decision.

The Board granted service connection for prostate cancer due to conceded in-service exposure to herbicides, effective from the date of claim.

The Board denied service connection for prostate cancer and denied increased ratings for the right knee strain, lumbar spine degenerative disc disease with sacroiliitis and IVDS. However, a 20 percent rating was granted for right knee instability.

The Board remands the claims for service connection for prostate cancer and erectile dysfunction, as secondary to prostate cancer, due to a pre-decisional error of the duty to assist under the Honoring our PACT Act of 2022.

The appeal of the proposed reduction of the Veteran's disability rating for prostate cancer was dismissed as it is not a decision that can be appealed to the Board.

The Board granted readjudication of the previously denied claim for prostate cancer and denied it for tinnitus, with the prostate cancer issue remanded for further development.